Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px
Document › Details

Biodesix, Inc.. (4/11/13). "Press Release: Biodesix Closes Series D Financing". Boulder, CO.

Organisations Organisation Biodesix Inc.
  Organisation 2 Chempetitive Group LLC
  Today CG Life LLC
  Group CG Life (Group)
Products Product VeriStrat® test
  Product 2 public relations / investor relations (services)
Index term Index term Biodesix–SEVERAL: investment, 201304 financing round Series D follow-on $8.8m from existing investors
     


Biodesix, Inc., a molecular diagnostics company advancing the development of innovative products for personalizing medicine, announced today that the company closed on $8.8 million in a follow-on sale of its Series D preferred shares. All funds were provided by existing shareholders of the company. The investment will be used for ongoing development of the company's technology platform and expansion of sales and marketing efforts to support Biodesix' first product, VeriStrat®. VeriStrat is a serum protein test that helps physicians guide therapy for patients with advanced non-small cell lung cancer (NSCLC).


About Biodesix

Biodesix is a molecular diagnostics company advancing the development of innovative products for personalizing medicine. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops and commercializes multivariate protein diagnostics based on their proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix' first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix' CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents. For more information on VeriStrat, please visit www.VeriStratSupport.com. For more information about Biodesix, please visit www.Biodesix.com.


This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.


Contacts

Chempetitive Group for Biodesix
Rachel Lear or Kelly Quigley
781-775-3640
Biodesix@Chempetitive.com

   
Record changed: 2016-03-22

Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px

More documents for Biodesix Inc.


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px